OMOCONAZOLE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C20H17Cl3N2O2
Molecular Weight	423.72
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C\C(N1C=CN=C1)=C(\OCCOC2=CC=C(Cl)C=C2)C3=CC=C(Cl)C=C3Cl

InChI

InChIKey=JMFOSJNGKJCTMJ-ZHZULCJRSA-N

InChI=1S/C20H17Cl3N2O2/c1-14(25-9-8-24-13-25)20(18-7-4-16(22)12-19(18)23)27-11-10-26-17-5-2-15(21)3-6-17/h2-9,12-13H,10-11H2,1H3/b20-14-

HIDE SMILES / InChI

Description
Sources: http://www.onmeda.fr/medicament/fongamil-93327055.html

Omoconazole is an azole antifungal drug, is used to treat candidiasis; dermatophytes and Pityriasis Versicolor

Approval Year

Conditions

Condition	Modality	Highest Phase	Product
Candida infections 20 Sources: http://www.onmeda.fr/medicament/fongamil-93327055.html	Curative	Approved 8583	Unknown Approved Use Unknown
Dermatomycosis 20 Sources: http://www.onmeda.fr/medicament/fongamil-93327055.html	Curative	Approved 8583	Unknown Approved Use Unknown
Pityriasis versicolor 4 Sources: http://www.onmeda.fr/medicament/fongamil-93327055.html	Curative	Approved 8583	Unknown Approved Use Unknown

Doses

Dose	Population	Adverse events
1 % single, topical Studied dose Dose: 1 % Route: topical Route: single Dose: 1 % Sources: https://pubmed.ncbi.nlm.nih.gov/3393168/	healthy Health Status: healthy Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/3393168/	Sources: https://pubmed.ncbi.nlm.nih.gov/3393168/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252	inhibitor 2438	inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2C19 2057 CYP1A2 2153

Drug as perpetrator

Target	Modality	Activity
CYP3A4 2633	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1671201#sid=170465847	yes [IC50 0.1738 uM]
CYP2C9 2497	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1645842#sid=170465847	yes [IC50 0.5495 uM]
CYP2C19 2141	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1671197#sid=170465847	yes [IC50 0.7762 uM]
CYP2D6 2546	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1645840#sid=170465847	yes [IC50 0.8709 uM]
CYP1A2 2333	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1671199#sid=170465847	yes [IC50 2.2877 uM]

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1671200#sid=170465847

PubMed

Title	Date	PubMed
Ultrastructural alterations of Candida albicans induced by a new imidazole antimycotic omoconazole nitrate.	1997	9194038

Patents

Sample Use Guides

In Vivo Use Guide

Cream; Topical; Omoconazole Nitrate 1%

Route of Administration: Topical

In Vitro Use Guide

The treatment of growing Candida cultures with fungistatic doses (0.4 to 4 micrograms/ml) of omoconazole nitrate (OMZ) produced the formation of a chain or cluster of cells. Thickening of the cell wall and accumulation of electrondense vesicles in the wall were clearly observed

Name

Type

Language

OMOCONAZOLE

Official Name

English

(Z)-1-(2,4-DICHLORO-.BETA.-(2-(P-CHLOROPHENOXY)ETHOXY)-.ALPHA.-METHYLSTYRYL)IMIDAZOLE

Preferred Name

English

Omoconazole [WHO-DD]

Common Name

English

omoconazole [INN]

Common Name

English

OMOCONAZOLE [MI]

Common Name

English

1H-IMIDAZOLE, 1-(2-(2-(4-CHLOROPHENOXY)ETHOXY)-2-(2,4-DICHLOROPHENYL)-1-METHYLETHENYL)-, (Z)-

Common Name

English

Classification Tree Code System Code

WHO-ATC

G01AF16